Savara Inc(SVRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SVRA Savara Inc

交易中 10-01 10:01:32 EDT

5.13

-0.03

-0.68%

最高5.24	最低5.10	成交量12.30万
今开5.13	昨收5.16	日振幅2.71%
总市值10.49亿	流通市值10.16亿	总股本2.05亿
成交额63.52万	换手率0.06%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":5.125,"timestamp":1790863285872,"preClose":5.16,"halted":0,"volume":122952,"delay":0,"changeRate":-0.006782945736434136,"floatShares":198198210,"shares":204657499,"eps":-0.578152,"marketStatus":"交易中","change":-0.035,"latestTime":"10-01 10:01:32 EDT","open":5.13,"high":5.24,"low":5.1,"amount":635158.1794272,"amplitude":0.027132,"askPrice":5.12,"askSize":310,"bidPrice":5.11,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-0.578152,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.16,"preHourTrading":{"tag":"盘前","latestPrice":5.16,"preClose":5.16,"latestTime":"08:58 EDT","volume":2120,"amount":10939.2,"timestamp":1790859538782,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.16,"latestTime":"19:30 EDT","volume":45954,"amount":237477.57,"timestamp":1790811002673,"change":0.04,"changeRate":0.007752,"amplitude":0.01938},"volumeRatio":0.430365,"impliedVol":2.1758,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/SVRA","defaultTab":"news","newsList":[{"id":"1174889253","title":"Savara将在2026年欧洲呼吸学会大会上再度呈现Molgramostim吸入溶液治疗自身免疫性肺泡蛋白沉积症（aPAP）的III期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1174889253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174889253?lang=zh_cn&edition=full","pubTime":"2026-08-25 04:06","pubTimestamp":1787601973,"startTime":"0","endTime":"0","summary":"Savara宣布，其关于Molgramostim吸入溶液（Molgramostim）治疗自身免疫性肺泡蛋白沉积症（aPAP）的III期临床试验结果，将在2026年欧洲呼吸学会（ERS）大会上以Encore形式再度呈现。此次展示是对该领域前沿研究的一次重要重申，亦为与会者提供了深入了解这一潜在疗法的机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181525658","title":"Savara旗下Molbreevi MAAS同步接受EMA与英国MHRA审查，预计分别于2027年Q1与2026年Q4揭晓结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1181525658","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181525658?lang=zh_cn&edition=full","pubTime":"2026-08-12 04:45","pubTimestamp":1786481154,"startTime":"0","endTime":"0","summary":"Savara Inc（Savara）正迎来关键监管节点。其药物Molbreevi的MAAS（市场授权申请）现已同时进入欧洲药品管理局（EMA）与英国药品和健康产品管理局（MHRA）的审查流程。根据最新时间表，EMA的决策窗口预计落在2027年第一季度，而MHRA则有望在2026年第四季度率先给出答案。这一进度差异，折射出不同监管机构各自的审评节奏与优先级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135683653","title":"Savara宣布欧洲和澳大利亚专利局授予Molbreevi*液体制剂专利，保护期至2041年3月","url":"https://stock-news.laohu8.com/highlight/detail?id=1135683653","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135683653?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:06","pubTimestamp":1785413196,"startTime":"0","endTime":"0","summary":"Savara Inc今日正式宣布，欧洲专利局与澳大利亚专利局已分别授予其核心药物Molbreevi*液体制剂的相关专利。这一里程碑式的进展，将为该公司在欧澳两大市场铺设一条长达近二十年的专利护城河。根据官方公告，这两项专利所提供的知识产权保护，将一直持续至2041年3月，为Savara的长期战略布局注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172355328","title":"Savara公司首席财务及行政官Dave Lowrance将于2026年7月15日卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=1172355328","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172355328?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:06","pubTimestamp":1780949172,"startTime":"0","endTime":"0","summary":"Savara公司宣布，其首席财务及行政官Dave Lowrance将于2026年7月15日正式离职。公司正着手进行继任规划，以确保相关职责的平稳过渡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144218221","title":"Savara在美国胸科学会2026年国际会议上公布其Molgramostim吸入溶液用于自身免疫性肺泡蛋白沉积症的Impala-2三期临床试验新生物标志物数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1144218221","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144218221?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:15","pubTimestamp":1779279333,"startTime":"0","endTime":"0","summary":"Savara Inc. 在近日举行的美国胸科学会2026年国际会议上，公布了其核心候选药物Molgramostim吸入溶液针对自身免疫性肺泡蛋白沉积症（aPAP）的Impala-2三期临床试验的最新生物标志物数据。\n此次公布的数据进一步揭示了该疗法的潜在作用机制与生物活性。生物标志物的动态变化为评估药物在患者体内的疗效反应提供了关键的科学依据。数据的呈现增强了业界对该疗法临床路径的理解，也标志着Savara在推进这一罕见呼吸疾病治疗方案的进程中取得了新的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128565481","title":"Savara公布IMPALA-2三期临床试验中莫格司亭吸入溶液治疗自身免疫性肺泡蛋白沉积症的新运动能力数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1128565481","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128565481?lang=zh_cn&edition=full","pubTime":"2026-05-19 02:56","pubTimestamp":1779130579,"startTime":"0","endTime":"0","summary":"Savara公司公布了其IMPALA-2三期临床试验中，关于莫格司亭吸入溶液治疗自身免疫性肺泡蛋白沉积症的新运动能力数据。该试验旨在评估莫格司亭对这一罕见肺部疾病患者的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168628720","title":"Savara Inc：处方药使用者付费法案目标审评日期延长三个月至2026年11月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=1168628720","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168628720?lang=zh_cn&edition=full","pubTime":"2026-04-16 04:06","pubTimestamp":1776283576,"startTime":"0","endTime":"0","summary":"生物制药公司Savara Inc宣布，美国食品药品监督管理局（FDA）已将其核心在研药物的处方药使用者付费法案（PDUFA）目标审评日期延长三个月。新的最终决定期限设定为2026年11月22日。\n此次延期为FDA完成对该公司新药申请（NDA）的全面审查提供了额外时间。PDUFA日期延后通常意味着监管机构需要更多数据或信息来做出最终批准决定，这在此类审查过程中属于常规程序。\n该公司表示将继续与FDA密切合作，以推进该药物的审评进程。此次延期不影响公司对其研发管线推进的战略规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106015571","title":"Savara宣布美国FDA延长莫格司亭吸入溶液治疗自身免疫性肺泡蛋白沉积症的生物制品许可申请审评周期","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015571","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106015571?lang=zh_cn&edition=full","pubTime":"2026-04-16 04:05","pubTimestamp":1776283522,"startTime":"0","endTime":"0","summary":"生物制药公司Savara Inc近日披露，美国食品药品监督管理局已决定延长其核心产品莫格司亭吸入溶液用于治疗自身免疫性肺泡蛋白沉积症的生物制品许可申请的审评时限。此次审评周期延长意味着监管机构需要更多时间对申报资料进行全面评估，但并未要求企业提交额外数据。该药物作为罕见呼吸系统疾病的重要候选疗法，其审评进展备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176735830","title":"Savara宣布英国MHRA受理Molgradex治疗自身免疫性肺泡蛋白沉积症的上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176735830","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176735830?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:21","pubTimestamp":1775564504,"startTime":"0","endTime":"0","summary":"Savara Inc宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex用于治疗自身免疫性肺泡蛋白沉积症的上市许可申请。\n根据公司披露的时间表，MHRA对Molgradex上市许可申请的决定预计将在2026年第四季度公布。与此同时，美国食品药品监督管理局（FDA）针对Molgradex生物制品许可申请设定的处方药用户付费法案目标日期为2026年8月22日。此外，欧洲药品管理局人用药品委员会对Molgradex上市许可申请的决定预计将于2027年第一季度作出。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199822860","title":"Savara宣布英国药品和保健品管理局接受Molgradex上市许可申请用于治疗自身免疫性肺泡蛋白沉积症","url":"https://stock-news.laohu8.com/highlight/detail?id=1199822860","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199822860?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:06","pubTimestamp":1775563586,"startTime":"0","endTime":"0","summary":"Savara Inc. 宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex®用于治疗自身免疫性肺泡蛋白沉积症（autoimmune PAP）的上市许可申请（MAA）。这一进展标志着该药物在英国监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115780051","title":"Savara宣布欧洲药品管理局验证Molbreevi*治疗自身免疫性肺泡蛋白沉积症的上市授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1115780051","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115780051?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:10","pubTimestamp":1774872613,"startTime":"0","endTime":"0","summary":"Savara Inc宣布，其针对自身免疫性肺泡蛋白沉积症（Autoimmune PAP）的治疗药物Molbreevi*的上市授权申请（MAA）已获得欧洲药品管理局（EMA）的正式验证。这一关键进展标志着该药物的审评程序在欧洲市场正式启动，为罕见呼吸系统疾病患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618990263","title":"Savara, Inc.盘中异动 大幅拉升5.16%报5.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618990263","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618990263?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:51","pubTimestamp":1773150685,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日21时51分，Savara, Inc.股票出现波动，股价快速拉升5.16%。截至发稿，该股报5.71美元/股，成交量9.1595万股，换手率0.05%，振幅4.79%。Savara, Inc.股票所在的生物技术行业中，整体涨幅为1.98%。其相关个股中，Longeveron Inc.、Mink Therapeutics, Inc.、Acurx Pharmaceuticals, Inc.涨幅较大，Biorestorative Therapies, Inc.、Mink Therapeutics, Inc.、Scisparc Ltd.较为活跃，换手率分别为576.95%、233.82%、145.88%，振幅较大的相关个股有Longeveron Inc.、Acurx Pharmaceuticals, Inc.、Artelo Biosciences, Inc.，振幅分别为54.24%、28.12%、20.22%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310215125a6b5a7f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310215125a6b5a7f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189257207","title":"Savara收到美国FDA第74日函件 显示该机构无计划召开咨询委员会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1189257207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189257207?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:08","pubTimestamp":1772831294,"startTime":"0","endTime":"0","summary":"Savara Inc（纳斯达克代码：SVRA）近日宣布，已收到美国食品药品监督管理局（FDA）发出的第74日函件。该函件明确指出，FDA目前并无召集咨询委员会会议的计划。\n这一进展标志着Savara在监管审批流程中迈出了重要一步。通常情况下，FDA会通过咨询委员会会议对创新疗法进行深入评估，而此次无需召开此类会议的决定，可能预示着审批流程的加速。\n公司表示将继续与FDA保持密切沟通，积极推进相关药物的审评工作。市场关注此举是否意味着Savara的研发项目将获得更快的监管反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163688181","title":"Savara公布Molbreevi*治疗自身免疫性肺泡蛋白沉积症研发项目的监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1163688181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163688181?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:06","pubTimestamp":1772831205,"startTime":"0","endTime":"0","summary":"Savara Inc（简称Savara）近日就其针对自身免疫性肺泡蛋白沉积症（Autoimmune PAP）的Molbreevi*研发项目，发布了最新的监管动态。\n公司方面表示，相关进展将有助于推动该疗法的后续开发进程，为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100831277","title":"Master Tec集团宣布Sediacom获1050万令吉授标函","url":"https://stock-news.laohu8.com/highlight/detail?id=1100831277","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100831277?lang=zh_cn&edition=full","pubTime":"2026-03-06 18:35","pubTimestamp":1772793354,"startTime":"0","endTime":"0","summary":"3月6日 - Master Tec集团宣布，其子公司Sediacom已正式接受价值1050万令吉的工程、采购、施工和调试（EPCC）合约。该合约内容涵盖275千伏地下电缆项目及国家能源公司（TNB）开关站扩建工程。\n此次中标将进一步巩固Master Tec在能源基建领域的市场地位，为公司未来业绩提供新的增长动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517794858","title":"Savara, Inc.盘中异动 急速上涨5.44%报2.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517794858","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517794858?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:31","pubTimestamp":1741185084,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时31分，Savara, Inc.股票出现异动，股价大幅拉升5.44%。截至发稿，该股报2.52美元/股，成交量3.8759万股，换手率0.02%，振幅4.60%。Savara, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为323.50%、252.09%、185.06%，振幅较大的相关个股有Aditxt, Inc.、Tango Therapeutics, Inc.、天境生物，振幅分别为23.90%、11.41%、11.10%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223124abe9b083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223124abe9b083&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510090333","title":"Savara, Inc.盘中异动 早盘股价大跌5.02%报2.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510090333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510090333?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:13","pubTimestamp":1739286836,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时13分，Savara, Inc.股票出现波动，股价急速下挫5.02%。截至发稿，该股报2.65美元/股，成交量5.2158万股，换手率0.03%，振幅4.30%。Savara, Inc.股票所在的生物技术行业中，整体跌幅为1.53%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2542.50%、824.87%、338.67%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为52.11%、43.92%、37.99%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112313569881c543&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112313569881c543&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OCEA","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507128620","title":"Savara, Inc.盘中异动 早盘快速上涨7.49%报2.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507128620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507128620?lang=zh_cn&edition=full","pubTime":"2025-01-30 23:58","pubTimestamp":1738252738,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日23时58分，Savara, Inc.股票出现异动，股价快速拉升7.49%。截至发稿，该股报2.87美元/股，成交量15.1275万股，换手率0.09%，振幅3.75%。Savara, Inc.股票所在的生物技术行业中，整体跌幅为0.27%。其相关个股中，Tectonic Therapeutic, Inc.、Kazia Therapeutics Limited、Alterity Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1590.55%、210.22%、196.46%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Alterity Therapeutics Limited、Immatics N V C/Wts 01/07/2025 ，振幅分别为61.86%、61.86%、56.41%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130235858961447a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130235858961447a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505864288","title":"Savara, Inc.盘中异动 早盘急速下挫5.03%报2.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505864288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505864288?lang=zh_cn&edition=full","pubTime":"2025-01-24 23:24","pubTimestamp":1737732252,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日23时24分，Savara, Inc.股票出现波动，股价快速下挫5.03%。截至发稿，该股报2.74美元/股，成交量4.2033万股，换手率0.02%，振幅3.99%。Savara, Inc.股票所在的生物技术行业中，整体跌幅为0.48%。其相关个股中，Transcode Therapeutics, Inc.、Pmgc Holdings Inc.、Dominari Holdings Inc.涨幅较大，Pmgc Holdings Inc.、Transcode Therapeutics, Inc.、Avenue Therapeutics, Inc.较为活跃，换手率分别为1772.31%、1139.13%、903.95%，振幅较大的相关个股有Windtree Therapeutics, Inc.、Transcode Therapeutics, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为66.25%、57.27%、55.79%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124232412abb75a44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124232412abb75a44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505028762","title":"Savara, Inc.盘中异动 大幅拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505028762","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505028762?lang=zh_cn&edition=full","pubTime":"2025-01-24 03:54","pubTimestamp":1737662040,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日03时54分，Savara, Inc.股票出现波动，股价大幅上涨5.05%。截至发稿，该股报2.91美元/股，成交量32.0744万股，换手率0.19%，振幅6.41%。Savara, Inc.股票所在的生物技术行业中，整体涨幅为1.31%。其相关个股中，Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Transcode Therapeutics, Inc.涨幅较大，Dogwood Therapeutics, Inc.、Hepion Pharmaceuticals, Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为7072.30%、6676.27%、896.79%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Transcode Therapeutics, Inc.，振幅分别为948.57%、172.73%、142.40%。Savara, Inc.公司简介：Savara Inc 是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124035400a22d484a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124035400a22d484a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com","stockEarnings":[{"period":"1week","weight":0.032},{"period":"1month","weight":-0.0427},{"period":"3month","weight":-0.1704},{"period":"6month","weight":-0.0719},{"period":"1year","weight":0.4454},{"period":"ytd","weight":-0.1443}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Savara Inc.于1995年12月在特拉华州注册成立。该公司是一家专注于罕见呼吸道疾病的临床阶段生物制药公司。其唯一的项目molgramostim吸入溶液（MOLBREEVI）是一种研究性吸入式生物制剂，正处于治疗自身免疫性肺泡蛋白沉积症的3期开发阶段，并已获得快速通道、突破性疗法和孤儿药资格认定。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.103891},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.038506},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.017596},{"month":4,"riseRate":0.571429,"avgChangeRate":0.029792},{"month":5,"riseRate":0.642857,"avgChangeRate":0.021325},{"month":6,"riseRate":0.5,"avgChangeRate":-0.018175},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.03016},{"month":8,"riseRate":0.5,"avgChangeRate":0.01418},{"month":9,"riseRate":0.5,"avgChangeRate":0.007273},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.136764},{"month":11,"riseRate":0.538462,"avgChangeRate":0.131385},{"month":12,"riseRate":0.538462,"avgChangeRate":0.21983}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Savara Inc(SVRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Savara Inc(SVRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}